Wellington Management Group LLP lifted its holdings in shares of Altimmune, Inc. (NASDAQ:ALT – Free Report) by 69.4% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 420,300 shares of the company’s stock after acquiring an additional 172,142 shares during the quarter. Wellington Management Group LLP owned 0.22% of Altimmune worth $1,278,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of ALT. Vanguard Group Inc. grew its stake in Altimmune by 23.3% in the 3rd quarter. Vanguard Group Inc. now owns 6,373,638 shares of the company’s stock valued at $24,029,000 after purchasing an additional 1,206,514 shares during the period. State Street Corp increased its position in shares of Altimmune by 42.2% during the 4th quarter. State Street Corp now owns 5,119,703 shares of the company’s stock valued at $18,482,000 after purchasing an additional 1,518,448 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Altimmune by 13.6% during the 4th quarter. Geode Capital Management LLC now owns 2,292,410 shares of the company’s stock valued at $8,278,000 after purchasing an additional 275,025 shares during the last quarter. Two Sigma Investments LP raised its stake in shares of Altimmune by 356.6% during the 3rd quarter. Two Sigma Investments LP now owns 1,996,848 shares of the company’s stock worth $7,528,000 after purchasing an additional 1,559,562 shares during the period. Finally, Goldman Sachs Group Inc. raised its stake in shares of Altimmune by 140.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,349,293 shares of the company’s stock worth $4,871,000 after purchasing an additional 787,036 shares during the period. 78.05% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
A number of equities analysts recently weighed in on ALT shares. Wall Street Zen raised shares of Altimmune from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. HC Wainwright restated a “buy” rating on shares of Altimmune in a report on Tuesday, July 28th. Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a research report on Tuesday, June 2nd. Leerink Partners initiated coverage on shares of Altimmune in a research note on Monday, June 22nd. They issued an “outperform” rating and a $10.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Altimmune in a research report on Wednesday, June 24th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.33.
Altimmune Stock Down 0.6%
Shares of NASDAQ:ALT opened at $3.27 on Friday. The firm has a market capitalization of $636.07 million, a PE ratio of -4.19 and a beta of 0.18. The company has a debt-to-equity ratio of 0.07, a quick ratio of 26.78 and a current ratio of 26.78. Altimmune, Inc. has a 52-week low of $2.56 and a 52-week high of $6.44. The firm has a fifty day moving average of $3.05 and a 200 day moving average of $3.15.
Altimmune (NASDAQ:ALT – Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. Altimmune had a negative return on equity of 31.41% and a negative net margin of 214,860.98%. As a group, research analysts anticipate that Altimmune, Inc. will post -0.58 EPS for the current fiscal year.
Altimmune Company Profile
Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.
Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.
Featured Stories
- Five stocks we like better than Altimmune
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.
